UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

ROIVANT SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Bermuda (State or other jurisdiction of incorporation or organization)

Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom (Address of principal executive offices) 98-1173944 (I.R.S. Employer Identification Number)

Not Applicable (Zip Code)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u> Common Shares, \$0.000000007 par value per share Warrants, each warrant to purchase one Common Share Name of each exchange <u>on which registered</u> The Nasdaq Global Select Market The Nasdaq Global Select Market

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. \boxtimes

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

Securities Act registration statement number to which this form relates: 333-256165

Securities to be registered pursuant to Section 12(g) of the Act:

None (Title of class)

None (Title of class)

Item 1. Description of Registrant's Securities to be Registered.

The securities to be registered hereby are the common shares, \$0.00000007 par value per share (the "Common Shares"), of Roivant Sciences Ltd. (the "Company") and warrants to purchase Common Shares (the "Warrants"). The description of the Common Shares and Warrants contained under the heading "Description of Securities" in the registration statement initially filed with the Securities and Exchange Commission on May 14, 2021, as amended from time to time (File No. 333-256165) (the "Registration Statement") to which this Form 8-A relates is incorporated herein by reference. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that are subsequently filed are hereby also incorporated by reference herein.

Item 2. Exhibits.

In accordance with the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed because no other securities of the registrant are registered on Nasdaq and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.

Very truly yours,

ROIVANT SCIENCES LTD.

By: /s/ Matt Maisak

Name: Matt Maisak Title: Authorized Signatory

Dated: September 3, 2021

2